GENNIEFY
Market News
Latest financial news and analysis from global markets
XAU/USD
Thor Explorations, IXICO, EMV Capital, Empire Metals, Coiled Therapeutics - Small Cap Snapshot
Thor Explorations Ltd (TSX-V:THX, AIM:THX, OTC:THXPF, FRA:T2X) delivered a strong first quarter, with revenue up to $74.3 million and net income rising to $46.7 million as a gold price of $4,820 per ounce more than offset lower sales volumes. The company is on track for 75,000 to 85,000 ounces of production this year and is advancing toward a final investment decision at its Douta project in Senegal. IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) is guiding for at least 15% revenue growth this year after a strong first half, with revenue up 23% and its order book growing 38% to £18.1 million. A £10 million fundraise will accelerate the company's TechBio strategy, including a partnership with Medidata, whose platform is used in 80% of FDA novel drug approvals. EMV Capital (AIM:EMVC, FRA:NTK1) grew assets under management 14% to £112.5 million in 2025, with group losses falling 83% to £0.6 million as revenue rose 17%. CEO Dr Ilian Iliev says the group is increasingly optimistic as portfolio companies approach key commercial and regulatory milestones. Empire Metals Ltd (AIM:EEE, OTCQX:EPMLF) has signed a definitive agreement to sell its 75% stake in a non-core gold asset near Kalgoorlie for A$750,000, freeing up capital and management focus for the Pitfield Titanium Project. Pitfield has a mineral resource of 2.2 billion tonnes grading 5.1% TiO₂, making it one of the largest titanium discoveries globally. Coiled Therapeutics (AIM:COIL) has begun trading on the US OTCQB market under the ticker COTXF, giving American investors dollar-denominated access to the oncology company's shares. CEO Sridhar Vempati says 2026 will be "a transformational year," with recent clinical data from its ongoing trial showing an 80% clinical benefit rate. Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk.
AMZN
Is It Too Late to Buy Cerebras Systems After the Stock Soared Following Its IPO?
The AI chipmaker's stock surged on its open day of trading last week, and it's still well above its IPO price.
AMD
Is It Too Late to Buy Cerebras Systems After the Stock Soared Following Its IPO?
The AI chipmaker's stock surged on its open day of trading last week, and it's still well above its IPO price.
GOOGL
Is It Too Late to Buy Cerebras Systems After the Stock Soared Following Its IPO?
The AI chipmaker's stock surged on its open day of trading last week, and it's still well above its IPO price.
NVDA
Is It Too Late to Buy Cerebras Systems After the Stock Soared Following Its IPO?
The AI chipmaker's stock surged on its open day of trading last week, and it's still well above its IPO price.
ABT
2 Reasons to Like ABBV and 1 to Stay Skeptical
Over the past six months, AbbVie’s shares (currently trading at $211.15) have posted a disappointing 9.8% loss, well below the S&P 500’s 11.5% gain. This might have investors contemplating their next move.
ABBV
2 Reasons to Like ABBV and 1 to Stay Skeptical
Over the past six months, AbbVie’s shares (currently trading at $211.15) have posted a disappointing 9.8% loss, well below the S&P 500’s 11.5% gain. This might have investors contemplating their next move.
INTC
Will a Kevin Warsh-Led Fed Sink the Stock Market? Here's What the Puzzle Pieces Suggest.
The chips appear to be stacked against Jerome Powell's successor in the early going.
NVDA
Will a Kevin Warsh-Led Fed Sink the Stock Market? Here's What the Puzzle Pieces Suggest.
The chips appear to be stacked against Jerome Powell's successor in the early going.
NVDA
It's Been 8 Months Since Klarna's IPO. Here's What Investors Should Know.
The stock has tanked, but the upside now looks good.
ABNB
It's Been 8 Months Since Klarna's IPO. Here's What Investors Should Know.
The stock has tanked, but the upside now looks good.
WMT
It's Been 8 Months Since Klarna's IPO. Here's What Investors Should Know.
The stock has tanked, but the upside now looks good.